Study on Granisetron for Nausea Control in Chemotherapy
Author Information
Author(s): A. Riviere, J.F. Heron, B.N. Bui, H. Neumann, D. Cupissol, D. Kamanabrou, A. Van de Merwe, J.P. Jordaan, W. Meinerz, L. Adenis, L. Cals, B. Chevallier, M. Schneider, P. Federspil, P. Fumoleau, M. Westerhausen, P. Kerbrat, H. Litschmann, C. Dott
Hypothesis
Does granisetron effectively control nausea and vomiting in patients receiving high-dose cisplatin chemotherapy?
Conclusion
Granisetron at doses of 10 or 40 µg/kg is more effective than 2 µg/kg in preventing nausea and vomiting from high-dose cisplatin.
Supporting Evidence
- 30.8% of patients in the 2 µg/kg group were complete responders.
- 61.5% of patients in the 10 µg/kg group were complete responders.
- 67.9% of patients in the 40 µg/kg group were complete responders.
- 82.7% of patients were treated with granisetron alone over the 7-day study period.
- Headache was the most common side effect, reported by 9.6% of patients.
Takeaway
This study shows that giving patients a higher dose of granisetron helps them feel less sick after chemotherapy.
Methodology
Randomized, double-blind study comparing three doses of granisetron in patients receiving cisplatin.
Limitations
Patients with certain health conditions were excluded, which may limit the generalizability of the results.
Participant Demographics
157 patients, 87 male and 70 female, with various types of cancer.
Statistical Information
P-Value
0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website